Mircera Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Mircera is a medication specifically developed to treat anemia linked to chronic kidney disease (CKD). It is a long-acting erythropoiesis-stimulating agent (ESA) that encourages red blood cell production to help maintain healthy hemoglobin levels. Mircera is usually given via intravenous or subcutaneous injections and is notable for its extended dosing schedule, often requiring administration only once every two to four weeks.

The main formulations of Mircera are injectable solutions and pre-filled syringes. Anemia associated with chronic kidney disease occurs when individuals with CKD experience a reduction in red blood cells, resulting in anemia. Its indications include anemia due to chronic kidney disease and anemia in cancer patients. The medication is distributed through hospitals, dialysis centers, specialty clinics, and retail pharmacies and is used by various patient groups, including adults and geriatric patients.

Tariffs have affected the mircera market by increasing costs related to imported biologic raw materials, syringe systems, and cold chain distribution services. These effects are more pronounced in regions dependent on imported anemia therapies, including asia pacific and parts of latin america. Dialysis centers face procurement cost pressures impacting treatment budgets. However, tariffs have encouraged regional manufacturing and filling operations. This improves long term supply reliability and supports broader patient access to anemia treatments.

The mircera market research report is one of a series of new reports from The Business Research Company that provides mircera market statistics, including mircera industry global market size, regional shares, competitors with a mircera market share, detailed mircera market segments, market trends and opportunities, and any further data you may need to thrive in the mircera industry. This mircera market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The mircera market size has grown strongly in recent years. It will grow from $2.84 million in 2025 to $3 million in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to rising chronic kidney disease prevalence, limitations of short acting esas, clinical validation of continuous erythropoietin receptor activators, expansion of dialysis infrastructure, improved anemia management protocols.

The mircera market size is expected to see strong growth in the next few years. It will grow to $3.69 million in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to growth in aging population, increasing dialysis patient numbers, demand for reduced injection frequency, expansion of specialty nephrology clinics, rising healthcare spending on ckd. Major trends in the forecast period include rising use of long acting esas, preference for extended dosing intervals, growing ckd patient population, increased treatment in dialysis centers, focus on stable hemoglobin management.

The rising prevalence of chronic kidney disease (CKD) is expected to drive the growth of the Mircera market in the coming years. Chronic kidney disease (CKD) is a medical condition marked by the gradual decline of kidney function, often linked to diseases such as diabetes and hypertension. The growing incidence of CKD is influenced by factors including aging populations, lifestyle changes, and improved diagnostic capabilities. Anemia, a frequent complication of CKD caused by reduced erythropoietin production, necessitates the use of erythropoiesis-stimulating agents like Mircera to effectively manage and maintain hemoglobin levels. For example, in June 2023, Kidney Research UK, a UK-based non-profit organization, reported that approximately 7.2 million people in the UK were living with chronic kidney disease, representing over 10% of the population. By 2033, this number is projected to increase to 7.61 million. Thus, the rising prevalence of CKD is driving the Mircera market.

Key players in the Mircera market are focusing on developing approved therapies specifically for pediatric patients to treat anemia associated with CKD. Pediatric patients with CKD-related anemia can benefit from Mircera (methoxy polyethylene glycol-epoetin beta), a long-acting erythropoiesis-stimulating agent (ESA) that promotes red blood cell production, reduces the need for frequent injections, lowers the risk of blood transfusions, and improves hemoglobin levels, thereby supporting overall growth, development, and quality of life. For instance, in April 2024, Vifor Pharma, a Switzerland-based pharmaceutical company, received FDA approval to expand the use of Mircera to pediatric patients aged 3 months to 17 years with CKD-associated anemia. This approval applies to both dialysis and non-dialysis patients, particularly those transitioning from another ESA after their hemoglobin levels have stabilized.

In January 2023, AstraZeneca plc, a UK-based biopharmaceutical company, acquired CinCor Pharma, Inc., a US-based clinical-stage biopharmaceutical company, in a deal valued at up to $1.8 billion. Through this acquisition, AstraZeneca aims to strengthen its cardiorenal pipeline by acquiring Baxdrostat (CIN-107), a highly selective oral aldosterone synthase inhibitor targeting hypertension and CKD. CinCor Pharma focuses on developing novel small-molecule therapies for treatment-resistant hypertension, primary aldosteronism, and other cardiorenal disorders.

Major companies operating in the mircera market are Roche

North America was the largest region in the mircera market in 2025. The regions covered in the mircera market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the mircera market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The mircera market consists of sales of solutions and pre-filled syringes designed to treat anemia caused by chronic kidney disease (CKD). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Mircera Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses mircera market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for mircera ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The mircera market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Formulation: Injectable Solution; Pre-filled Syringes
• 2) By Indication: Anemia Due to Chronic Kidney Disease; Anemia in Cancer Patients
• 3) By Distribution Channel: Hospitals; Dialysis Centers; Specialty Clinics; Retail Pharmacies
• 4) By End User Patients: Adult Patients; Geriatric Patients
• Companies Mentioned: Roche
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.